Consensus Rigel Pharmaceuticals, Inc.

Stocks

RIGL

US7665597024

Pharmaceuticals

Market Closed - Nasdaq 16:00:00 2026-09-16 EDT			5-day change	1st Jan Change
44.48 ^USD	+0.27%		-5.80%	+3.85%

08-13	Rigel Pharmaceuticals Announces Availability Of VEPPANU (Vepdegestrant) For Patients With ER+/HER2-, ESR1-Mutated Advanced Or Metastatic Breast Cancer	CI
08-13	Rigel Says Breast Cancer Drug Veppanu Now Available in US, Puerto Rico	MT

Evolution of the Average Target: Rigel Pharmaceuticals, Inc.

Evolution of the Target Price: Rigel Pharmaceuticals, Inc.

Changes in Analyst Recommendations: Rigel Pharmaceuticals, Inc.

446d0edcd894c9834bbdfd0b.t0JamNnLsc2zQ31QSF0P6kLveYXQtyyevpreA9eAG4Y.h3Qj1u-vxIr8DiUpLTt-nQS5Fvyq-UKm9a-2UO7YUMiAe3fusJPQhYMTSQ~16aa1118291b1f3f90524da9c811f56e

Analysts' recommendations: Rigel Pharmaceuticals, Inc.

11-06	Jefferies Upgrades Rigel Pharmaceuticals to Buy From Hold, Adjusts PT to $42 From $23	MT
25-10-08	Rigel Pharmaceuticals, Inc. Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDS	CI
25-08-05	Rigel Pharmaceuticals Q2 revenue beats estimates	RE
25-03-05	B. Riley Raises Price Target on Rigel Pharmaceuticals to $24 From $20, Keeps Neutral Rating	MT
24-12-10	B. Riley Cuts Price Target on Rigel Pharmaceuticals to $20 From $27, Keeps Neutral Rating	MT
24-12-06	B. Riley Adjusts Price Target on Rigel Pharmaceuticals to $27 From $17, Maintains Neutral Rating	MT
24-03-07	Citigroup Adjusts Rigel Pharmaceuticals' Price Target to $4 From $3, Maintains Buy Rating	MT
24-02-26	B. Riley Lifts Rigel Pharmaceuticals' PT to $1.75 From $1.25 After Announced Purchase of US Rights to Gavreto From Blueprint Medicines; Keeps Neutral Rating	MT
23-11-09	B. Riley Trims Rigel Pharmaceuticals' PT to $1.25 From $1.75, Lowers Peak Sales Estimate for Rezlidhia; Maintains Neutral Rating	MT
23-04-03	Piper Sandler Assumes Neutral Rating on Rigel Pharmaceuticals With $2 Price Target	MT
23-03-09	Citigroup Adjusts Price Target on Rigel Pharmaceuticals to $3 From $2, Keeps Buy Rating	MT
22-12-02	Citigroup Upgrades Rigel Pharmaceuticals to Buy From Neutral, Raises Price Target to $2 From $1.50	MT
22-08-18	HC Wainwright Adjusts Rigel Pharmaceuticals' Price Target to $15 from $7, Keeps Buy Rating	MT
22-08-17	Piper Sandler Adjusts Price Target on Rigel Pharmaceuticals to $2 From $1, Maintains Neutral Rating	MT
22-08-03	Cantor Fitzgerald Raises Rigel Pharmaceuticals Price Target to $2 From $1, Maintains Neutral Rating	MT
22-06-09	BMO Lowers Rigel Pharmaceuticals' Price Target to $3 From $7, Maintains Outperform Rating	MT
22-06-09	B. Riley Lowers Rigel Pharmaceuticals' Price Target to $1.25 from $4 After Disappointing Trial Data on Fostamatinib, Keeps Neutral Rating	MT
22-06-09	Citigroup Downgrades Rigel Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $0.80 From $7	MT
22-06-09	Piper Sandler Cuts Rigel Pharmaceuticals to Neutral From Overweight, Price Target to $1 From $7	MT
22-06-09	Jefferies Lowers Rigel Pharmaceuticals to Hold From Buy, Price Target to $1 From $8	MT
22-06-08	HC Wainwright Adjusts Rigel Pharmaceuticals' Price Target to $7 from $11, Keeps Buy Rating	MT
22-06-08	Cantor Fitzgerald Downgrades Rigel Pharmaceuticals to Neutral from Overweight	MT
22-03-23	B. Riley Initiates Rigel Pharmaceuticals at Neutral with $4 Price Target, Notes Hidden Risks in Phase III Protocol for Warm Autoimmune Hemolytic Anemia	MT
20-11-09	Rigel Pharmaceuticals : JPMorgan Downgrades Rigel Pharmaceuticals to Neutral From Overweight	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	RIGEL PHARMACEUTICALS, INC.					+42.02%
	ELI LILLY AND COMPANY					+16.61%
	JOHNSON & JOHNSON					+4.01%
	ABBVIE INC.					+5.92%
	ROCHE HOLDING AG					+3.88%
	NOVARTIS AG					+10.12%
	ASTRAZENECA PLC					+29.67%
	AMGEN INC.					+3.3%
	NOVO NORDISK A/S					+12.42%
	GILEAD SCIENCES, INC.					+8.1%
	Average					+13.60%
	Weighted average by Cap.					+10.72%